Biosimilar use in the United States: An analysis of filgrastim and infliximab

被引：0
|
作者：
Dutcher, Sarah K. [1 ]
Eworuke, Efe [1 ]
Fazio-Eynullayeva, Elnara [2 ,3 ]
Dee, Elizabeth [2 ,3 ]
Nguyen, Michael D. [1 ]
Panozzo, Catherine A. [2 ,3 ]
机构：
[1] US FDA, Silver Spring, MD USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Harvard Pilgrim Hlth Care Inst, Boston, MA USA
来源：
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY | 2019年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
978
引用
收藏
页码：475 / 475
页数：1
相关论文
共 50 条
  • [31] FDA advisers recommend approval of biosimilar filgrastim
    Traynor, Kate
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2015, 72 (04) : 262 - +
  • [32] Switching from infliximab to biosimilar
    Baker, Holly
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (07): : 475 - 475
  • [33] Adherence patterns in naïve and prevalent use of infliximab and its biosimilar
    Chibuike J. Alanaeme
    Sujith Sarvesh
    Cynthia Y. Li
    Sasha Bernatsky
    Jeffrey R. Curtis
    Huifeng Yun
    BMC Rheumatology, 6
  • [34] OUTPATIENT EXPERIENCE WITH BIOSIMILAR FILGRASTIM IN PATIENTS WITH LYMPHOID NEOPLASMS: LESSONS FROM ROUTINARY USE
    Broccoli, A.
    Stefoni, V.
    Pellegrini, C.
    Derenzini, E.
    Gandolfi, L.
    Quirini, F.
    Casadei, B.
    Maglie, R.
    Argnani, L.
    Zinzani, P. L.
    HAEMATOLOGICA, 2014, 99 : 747 - 748
  • [35] First Biosimilar Drug Approved for Sale in the United States
    Hede, Karyn
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (07):
  • [36] Have the biosimilar floodgates been opened in the United States?
    Courtenay C. Brinckerhoff
    Kristel Schorr
    Nature Reviews Drug Discovery, 2015, 14 : 303 - 304
  • [37] Biosimilar pharmaceutical products in the United States: Foundations and frameworks
    Baker, Jeffrey
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 247
  • [38] Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis
    Mansell, Kerry
    Bhimji, Hishaam
    Eurich, Dean
    Mansell, Holly
    BMC HEALTH SERVICES RESEARCH, 2019, 19 (01)
  • [39] Considerations in the development and control of biosimilar manufacturing in the United States
    Baker, Jeffrey
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 251
  • [40] Inpatient Infliximab Biosimilar Cost-Savings: Cost Analysis of Inpatient Treatment with Originator Infliximab (Remicade™) versus Biosimilar Infliximab (Renflexis™) for Acute Severe Ulcerative Colitis
    Cappuccio, Joseph M.
    Mehta, Neev
    Pellish, Randall
    DIGESTIVE DISEASES, 2024, 42 (05)
12345